LRMR vs. TVTX, OCS, ATXS, VERV, ANL, TRDA, KALV, APLT, LXRX, and YMAB
Should you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Travere Therapeutics (TVTX), Oculis (OCS), Astria Therapeutics (ATXS), Verve Therapeutics (VERV), Adlai Nortye (ANL), Entrada Therapeutics (TRDA), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Lexicon Pharmaceuticals (LXRX), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Travere Therapeutics (NASDAQ:TVTX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
Travere Therapeutics received 25 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 60.87% of users gave Larimar Therapeutics an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
Travere Therapeutics presently has a consensus price target of $16.69, indicating a potential upside of 170.54%. Larimar Therapeutics has a consensus price target of $20.00, indicating a potential upside of 175.10%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Travere Therapeutics.
In the previous week, Larimar Therapeutics had 4 more articles in the media than Travere Therapeutics. MarketBeat recorded 9 mentions for Larimar Therapeutics and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.73 beat Larimar Therapeutics' score of 0.19 indicating that Larimar Therapeutics is being referred to more favorably in the news media.
91.9% of Larimar Therapeutics shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by insiders. Comparatively, 4.3% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Travere Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Larimar Therapeutics has lower revenue, but higher earnings than Travere Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
Larimar Therapeutics has a net margin of 0.00% compared to Larimar Therapeutics' net margin of -87.94%. Travere Therapeutics' return on equity of -35.69% beat Larimar Therapeutics' return on equity.
Summary
Larimar Therapeutics beats Travere Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Larimar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Larimar Therapeutics Competitors List
Related Companies and Tools
